


PATENT ANALYSIS


MAJOR APPLICANT

264 patents were selected from 2006 to 2019. Many actors are present (>200) and the three main applicants are Neurosearch, Novartis and SmithKline Beecham Corp. However, considering Neurosearch alone, it has only 4.2% of the selected patents. Neurosearch claims 12 new chemical entities. The majority of them talk about modulator of nicotinic acetylcholine receptors. Due to their pharmacological profile, these compounds may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system, the peripheral nervous system, endocrine diseases or disorders, diseases or disorders related to inflammation, including skin inflammation such as acne and rosacea, receptors. Due to their pharmacological profile, these compounds may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system, the peripheral nervous system, endocrine diseases or disorders, diseases or disorders related to inflammation, including skin inflammation such as acne and rosacea, receptors. Due to their pharmacological profile, these compounds may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system, the peripheral nervous system, endocrine diseases or disorders, diseases or disorders related to inflammation, including skin inflammation such as acne and rosacea.



ANALYSIS BY TECHNOLOGY

Patent type: most of the patent claims new use of molecules (37%) and new chemical entities (32%). These patents applications claim also other pathology such as psoriasis, rosacea, eczema and cancer. Patent type: most of the patent claims new use of molecules (37%) and new chemical entities (32%). These patents applications claim also other pathology such as psoriasis, rosacea, eczema and cancer. Patent type: most of the patent claims new use of molecules (37%) and new chemical entities (32%). These patents applications claim also other pathology such as psoriasis, rosacea, eczema and cancer. Patent type: most of the patent claims new use of molecules (37%) and new chemical entities (32%). These patents applications claim also other pathology such as psoriasis, rosacea, eczema and cancer. Patent type: most of the patent claims new use of molecules (37%) and new chemical entities (32%). These patents applications claim also other pathology such as psoriasis, rosacea, eczema and cancer.



Network on main assignors/main technology in red main assignor in purple assignors in green technology

SELECTED PATENTS WITH HIGH INNOVATION POTENTIAL

Patent	Title	Assignee	Technology	Innovation potential
EP2009402A1	Methods for the treatment of neurological disorders	Genentech	Ph	+8
EP2009402A1	Substrate 1, triazopyridines for use as GPCR inhibitors	Amgen Inc Amgen Corp	Med	+9
EP2009402A1	Alkylphosphonic derivatives useful as modulators of nicotinic acetylcholine receptors	Novartis	Med	+7
EP2009402A1	Indoles, 2H-pyridin [1,2-a] and 1,8-diazabicyclo-octanes which act as GPCR agonists	Amgen Amgen Inc	Ph	+5
EP2009402A1	Methodology of the production of GPCR receptor modulators for the treatment of neurodegenerative diseases	Amgen Amgen Inc	Ph	+7
EP2009402A1	Use of adenosine nucleoside analogs as agonists and for the treatment of cancer	Amgen Amgen Inc	Ph	+1
EP2009402A1	Derivatives of a GPCR antagonist	Amgen Amgen Inc	Formulation	+1
EP2009402A1	Therapeutically active triazoles and their use	Amgen Amgen Inc	Med	+1
EP2009402A1	Alkylphosphonic derivatives containing a hydroxyphosphonic group or hydroxyphosphonyl group	Novartis Novartis Pharma AG	Med	+6
EP2009402A1	Derivatives of a GPCR antagonist	Pharmaceuticals	Formulation	+1
EP2009402A1	Therapeutically active triazoles and their use	Amgen Amgen Inc	Med	+1
EP2009402A1	Alkylphosphonic derivatives containing a hydroxyphosphonic group or hydroxyphosphonyl group	Novartis Novartis Pharma AG	Med	+6

Order sorted by "Innovation potential" column, descending order.

The "Innovation potential" (KnowMade®) is a numerical value ranging from -10 to +10 calculated from the following parameters:

- Potential duration of innovation (technological fundament, innovation intensity in the sector of application, type of applicant, competitive strength, lifetime of patent, copyability).
- Technology impact (type of innovation, number of independent claims, number of words per independent claim, number of words in the description, quality of the search report).
- Potential market volume (number of potential applications, sector coverage, designated states for protection, market size).

4. BIBLIOGRAPHY ANALYSIS

First type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The second type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The third type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The fourth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The fifth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The sixth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The seventh type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The eighth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The ninth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The tenth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%).

Second type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The third type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The fourth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The fifth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The sixth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The seventh type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The eighth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The ninth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%). The tenth type: most of the papers discuss the use of antibodies (27%) and/or genetic markers (27%).




Figure 1: Evolution of the number of publications on the use of antibodies (27%) and/or genetic markers (27%) in the field of pathology and epidemiology from 1980 to 2000.